Searching across hundreds of databases
Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.
Integrated Clinical Trials is a virtual database currently indexing clinical trials from: EU Clinical Trials Register and ClinicalTrials.gov.
(last updated: Nov 28, 2022)
Clinical Trials Information| Database | Title | Recruitment | Conditions | Intervention | Sponsored By | Gender | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Clinicaltrials.gov | MT2004-30: Tomotherapy for Solid Tumors | Terminated | Brain and Central Nervous System Tumors, Kidney Cancer, Liver Cancer, Retinoblastoma, Sarcoma | Biological, Drug, Drug, Drug, Drug, Drug, Procedure, Radiation, Radiation, Drug, Radiation - filgrastim, busulfan, etoposide, ifosfamide, melphalan, thiotepa, stem cell transplantation, tomotherapy, total marrow irradiation, Mesna, Whole lung radiation | Masonic Cancer Center, University of Minnesota, Other | N/A - 70 Years | Phase 1 | Interventional | RATIONALE: A peripheral blood stem cell transplant or bone marrow transplant using stem cells from the patient may be able to replace immune cells that were destroyed by chemotherapy and image-guided intensity-modulated radiation therapy used to kill tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of bone marrow radiation therapy followed by an autologous stem cell transplant in treating patients with high-risk or relapsed solid tumors. | ||
Clinicaltrials.gov | Allogeneic Hematopoietic Cell Transplantation for Severe Systemic Sclerosis | Completed | Systemic Scleroderma, Severe Systemic Sclerosis | Drug, Drug, Drug, Radiation, Procedure, Procedure, Procedure, Other, Other, Procedure - fludarabine phosphate, Mycophenolic Acid, tacrolimus, total-body irradiation, bone marrow transplantation, reduced intensity allogeneic hematopoietic stem cell transplantation, quality-of-life assessment, laboratory biomarker analysis, flow cytometry, biopsy | Fred Hutchinson Cancer Research Center, National Institute of Allergy and Infectious Diseases (NIAID), Other, NIH | N/A - 70 Years | Phase 1/Phase 2 | Interventional | The purpose of the study is to examine the safety and effectiveness of a reduced intensity conditioning regimen and allogeneic bone marrow transplant for people with systemic sclerosis. In an allogeneic bone marrow transplant procedure, bone marrow is taken from a healthy donor and transplanted into the patient. Bone marrow can be donated by a family member or an unrelated donor who is a complete tissue type match. Participants will receive the chemotherapy and low dose radiation conditioning regimen consisting of the following: Fludarabine will be given intravenously for 5 days. Cyclophosphamide will be given intravenously on the first and second day. After completing the fludarabine and cyclophosphamide, patients will receive a single low dose of total body irradiation. The next day, patients will receive the allogeneic bone marrow transplant. On the third and fourth day after the transplant, patients will receive high dose intravenous cyclophosphamide. This is given to help prevent two complications: (1) graft rejection, which occurs when the body's immune system rejects the donor bone marrow, and (2) graft-versus-host disease (GVHD), which is when the donor immune cells attack the patient's normal tissues. On the fifth day after the transplant, patients will start receiving two additional medications: tacrolimus and mycophenolic acid (MPA, Myfortic), to help prevent GVHD. Patients will receive mycophenolic acid for about 5 weeks and tacrolimus for about 6 months. Also beginning on the fifth day after the transplant, patients will receive daily injections of a growth factor called granulocyte-colony stimulating factor (G-CSF), which is a protein that increases the white blood cell count; G-CSF will be continued until the patient's white blood cell count has returned to normal levels. Patients will remain closely monitored either in the outpatient clinic setting or in the hospital for approximately 2-3 months after the transplant, but possibly longer if there are complications. Follow-up study visits will occur at 6 months and then at 1, 2, 3, 4, and 5 years after the transplant. Study researchers will keep track of the patient's medical condition after leaving the transplant center by phone calls or mailings to patients and their doctors once a year for the rest of the study participants' lives. | ||
|
Clinicaltrials.gov | Everolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma | Completed | Multiple Myeloma and Plasma Cell Neoplasm | Drug, Genetic, Genetic, Genetic, Other, Other, Procedure - everolimus, DNA analysis, protein analysis, western blotting, flow cytometry, laboratory biomarker analysis, biopsy | Mayo Clinic, National Cancer Institute (NCI), Other, NIH | 18 Years - N/A | Phase 2 | Interventional | RATIONALE: Everolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer. PURPOSE: This phase II trial is studying how well everolimus works in treating patients with relapsed or refractory multiple myeloma. | ||
|
Clinicaltrials.gov | Prospective Randomized Trial On RadiaTion Dose Estimates Of CT AngIOgraphy In PatieNts Scanned With A 100kV Protocol | Unknown status | Coronary Disease | Radiation, Radiation - tube voltage, tube voltage | Deutsches Herzzentrum Muenchen, Other | 18 Years - N/A | Phase 4 | Interventional | The objective of this study is to compare radiation dose of a 100kV scan protocol to the standard 120kV scan protocol. We hypothesize that the 100kV scan protocol is associated with a reduction in dose estimates of at least 20%, while the diagnostic image quality is not inferior. Secondary endpoints of the study include quantitative image quality parameters, diagnostic accuracy for 120 vs.100kV studies compared to invasive angiography in patients who underwent subsequent invasive coronary angiography | ||
|
Clinicaltrials.gov | Cetuximab, 5-FU and Radiation as Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer | Terminated | Rectal Cancer | Drug, Drug, Radiation - Cetuximab, 5-Fluorouracil, Radiation | Dana-Farber Cancer Institute, Massachusetts General Hospital, Beth Israel Deaconess Medical Center, Brigham and Women's Hospital, Bristol-Myers Squibb, Other, Other, Other, Other, Industry | 18 Years - N/A | Phase 2 | Interventional | The standard treatment for rectal cancer is to receive the chemotherapeutic drug 5-fluorouracil (5-FU) with radiation therapy before having surgery to remove the rectal cancer. This is known as neoadjuvant chemoradiotherapy. The purpose of this research study is to determine if Cetuximab improves the benefits of neoadjuvant chemoradiotherapy when given with 5-FU and radiation therapy. | ||
|
Clinicaltrials.gov | Brain Effects of Sacral Neuromodulation | Completed | Urinary Tract Disease | Radiation, Radiation - Baseline neuroimaging, Neuroimaging during sacral neuromodulation | University Hospital Inselspital, Berne, Other | 18 Years - N/A | N/A | Interventional | Sacral neuromodulation (SNM) has become an accepted treatment for patients with refractory lower urinary tract dysfunction such as urgency frequency syndrome, urgency incontinence, non-obstructive chronic urinary retention and chronic pelvic pain syndrome. Modulation of central afferent activity is considered critical to this therapeutic effect but the neural mechanisms are poorly understood. We hypothesize that SNM has a significant effect on brain activity detectable by positron emission tomography (PET). | ||
|
Clinicaltrials.gov | IMC-A12 in Treating Young Patients With Relapsed or Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor or Other Solid Tumor | Completed | Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Unspecified Childhood Solid Tumor, Protocol Specific | Biological, Other, Other - cixutumumab, pharmacological study, laboratory biomarker analysis | National Cancer Institute (NCI), NIH | 1 Year - 21 Years | Phase 1 | Interventional | This phase I clinical trial is studying the side effects and best dose of IMC-A12 in treating young patients with relapsed or refractory Ewing sarcoma/peripheral primitive neuroectodermal tumor or other solid tumors. Monoclonal antibodies, such as IMC-A12, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. | ||
|
Clinicaltrials.gov | Using Fluorine-18-Labeled Fluoro-Misonidazole Positron Emission Tomography To Detect Hypoxia in Head and Neck Cancer Patients | Active, not recruiting | Head and Neck Cancer | Radiation, Device, Device, Device - fluorine-18-labeled fluoro-misonidazole (18F-FMISO), 18F-FMISO PET scan, MRI, FDG PET/CT scan | Memorial Sloan Kettering Cancer Center, Other | 18 Years - N/A | N/A | Interventional | The main purpose of this study is to evaluate low oxygen areas called hypoxia within tumors. These low oxygen areas are thought to be the reason why tumors are more resistant to chemotherapy and radiation treatment. An imaging technique using a hypoxia tracer called fluoromisonidazole (FMISO) can detect low oxygen areas within a tumor. This imaging technique, called a PET scan, uses positively charged particles to detect slight changes in the body's biochemistry and metabolism. FMISO PET scans have been performed in patients with head and neck cancer and have shown the ability to detect low oxygen areas within tumors. | ||
|
Clinicaltrials.gov | PET Imaging With Cu-64 Labeled Trastuzumab in HER2+ Metastatic Breast Cancer | Completed | Breast Cancer | Radiation, Radiation - PET Imaging With Cu-64 Labeled Trastuzumab, PET Imaging With Cu-64 Labeled Trastuzumab | Memorial Sloan Kettering Cancer Center, Other | Female | 18 Years - N/A | Phase 1 | Interventional | The purpose of this study is to learn more about how a new study agent works inside the body. The study agent is a protein called 64Cu-trastuzumab. This is a radioactive tracer that was developed at MSKCC to target HER2 protein on cancer cells. A radioactive tracer is a small amount of radioactive dye that follows something else that is not radioactive In this study the study agent, 64Cu-trastuzumab, is the tracer and what's being followed is trastuzumab (Herceptin™). By giving you this tracer after you have treatment with trastuzumab (Herceptin™), we will be able to use PET scans to show us which parts of your body and tumor sites the Herceptin goes to. This will help us to understand better how Herceptin works in the body to fight cancer. | |
|
Clinicaltrials.gov | Bevacizumab, Combination Chemotherapy, and Radiation Therapy in Treating Patients Undergoing Surgery For Locally Advanced Pancreatic Cancer | Completed | Pancreatic Cancer | Biological, Drug, Drug, Drug, Other, Other, Procedure, Procedure, Procedure, Radiation - bevacizumab, fluorouracil, gemcitabine hydrochloride, oxaliplatin, immunohistochemistry staining method, laboratory biomarker analysis, conventional surgery, endoscopic biopsy, laparoscopy, radiation therapy | Abramson Cancer Center of the University of Pennsylvania, National Cancer Institute (NCI), Other, NIH | 18 Years - 120 Years | Phase 2 | Interventional | RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as gemcitabine, oxaliplatin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving bevacizumab together with combination chemotherapy and radiation therapy may kill more tumor cells. PURPOSE: The phase II trial is studying the side effects and how well giving bevacizumab together with gemcitabine, oxaliplatin, fluorouracil, and radiation therapy works in treating patients undergoing surgery for locally advanced pancreatic cancer. | ||
|
Clinicaltrials.gov | F-18 16 Alpha-Fluoroestradiol-Labeled Positron Emission Tomography in Predicting Response to First-Line Hormone Therapy in Patients With Stage IV Breast Cancer | Completed | Estrogen Receptor-positive Breast Cancer, Progesterone Receptor-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer | Radiation, Radiation, Procedure, Procedure, Procedure, Other - F-18 16 alpha-fluoroestradiol, fludeoxyglucose F 18, positron emission tomography, positron emission tomography, computed tomography, laboratory biomarker analysis | National Cancer Institute (NCI), NIH | Female | 18 Years - N/A | Phase 2 | Interventional | This phase II trial is studying how well F-18 16 alpha-fluoroestradiol (FES) imaging works in predicting response to first-line hormone therapy in women with hormone receptor-positive metastatic breast cancer. Diagnostic procedures, such as FES imaging, may help predict how well patients will respond to hormone therapy and may help plan the best treatment. | |
|
Clinicaltrials.gov | Erlotinib and Surgery in Treating Patients With Head and Neck Cancer That Can Be Removed by Surgery | Completed | Head and Neck Cancer | Drug, Genetic, Genetic, Other, Other, Other, Other, Procedure, Procedure - erlotinib hydrochloride, protein analysis, western blotting, immunohistochemistry staining method, laboratory biomarker analysis, liquid chromatography, mass spectrometry, neoadjuvant therapy, therapeutic conventional surgery | Wake Forest University Health Sciences, National Cancer Institute (NCI), Other, NIH | 18 Years - 120 Years | Early Phase 1 | Interventional | RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment with erlotinib. PURPOSE: This clinical trial is studying how well erlotinib works when given before surgery in treating patients with head and neck cancer that can be removed by surgery. | ||
|
Clinicaltrials.gov | Avastin in Combination With Radiation (XRT) & Temozolomide, Followed by Avastin, Temozolomide and Irinotecan for Glioblastoma (GBM) and Gliosarcomas | Completed | Glioblastoma, Gliosarcoma, Brain Tumor | Drug, Drug, Radiation, Drug - Avastin, Temozolomide, Radiation Therapy (XRT), Irinotecan | Duke University, Genentech, Inc., Schering-Plough, Other, Industry, Industry | 18 Years - N/A | Phase 2 | Interventional | Primary objective: To use overall survival to assess the efficacy of the combination of radiation therapy, temozolomide and Avastin followed by Avastin, temozolomide, and irinotecan in the treatment of grade IV malignant glioma patients following surgical resection. Secondary objective: To determine the progression-free survival following the combination of radiation therapy, temozolomide and Avastin followed by Avastin, temozolomide, and irinotecan. Exploratory Objective: To explore the relationship between biomarkers and outcome (overall survival and progression-free survival) among patients with grade IV malignant glioma treated with radiation therapy, temozolomide and Avastin followed by Avastin, temozolomide, and irinotecan. To describe the toxicity of radiation therapy,temozolomide and Avastin followed by Avastin, temozolomide, and irinotecan. | ||
|
Clinicaltrials.gov | SCRT Versus Conventional RT in Children and Young Adults With Low Grade and Benign Brain Tumors | Unknown status | Low Grade Gliomas, Craniopharyngioma, Ependymomas, Meningiomas | Radiation, Radiation - Stereotactic Conformal radiotherapy, Conventional radiotherapy | Tata Memorial Hospital, Terry Fox Foundation, Other, Other | 3 Years - 25 Years | Phase 3 | Interventional | Brain tumours are the commonest solid tumours in children and the second most common neoplasms overall in this patient population. Radiotherapy plays an important part in the management in a majority of these tumours. While the cure rates of these tumours, especially the benign and low grade ones are quite encouraging, the treatment itself may lead to some late sequelae, which could have significant implications in the quality of life in these long-term survivors. Stereotactic conformal radiotherapy (SCRT) is a modern high-precision radiotherapy technique, which reduces the volume of normal brain irradiated and has the capability to minimise the doses to critical structures. The present study is designed to prospectively estimate the incidence and severity of neuropsychological, cognitive and neuroendocrine dysfunction following radiotherapy delivered with conventional and stereotactic techniques and would be one of the most comprehensive studies providing very important longitudinal and reliable data regarding these sequelae. The study involving 200 patients would be to the best of our knowledge not only the largest ever study conducted so far but also the only randomised trial assessing these sequelae in patients receiving focal brain irradiation. The study also examines whether the physical advantages of modern technological progress translate in clinical benefit. This could have significant implications in the radiotherapeutic management of children and young adults with brain tumours. The study is unique in design in terms of evaluating the efficacy of SCRT with respect to conventional radiotherapy in terms of long term tumour control and treatment related complications. | ||
|
Clinicaltrials.gov | PEG-Interferon Alfa-2b and Sorafenib in Treating Patients With Unresectable or Metastatic Kidney Cancer | Terminated | Kidney Cancer | Biological, Drug, Genetic, Genetic, Genetic, Other, Other, Other - PEG-interferon alfa-2b, Sorafenib, gene expression analysis, polymerase chain reaction, reverse transcriptase-polymerase chain reaction, flow cytometry, immunoenzyme technique, laboratory biomarker analysis | Thomas Olencki, Schering-Plough, Other, Industry | 18 Years - N/A | Phase 1 | Interventional | RATIONALE: PEG-interferon alfa-2b may interfere with the growth of tumor cells. Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It may also stop the growth of kidney cancer by blocking blood flow to the tumor. Giving PEG-interferon alfa-2b together with sorafenib may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of PEG-interferon alfa-2b and sorafenib in treating patients with unresectable or metastatic kidney cancer. | ||
|
Clinicaltrials.gov | Vaccine Therapy and Celecoxib in Treating Patients With Metastatic Nasopharyngeal Cancer | Unknown status | Head and Neck Cancer | Biological, Drug, Other, Other, Other - Ad5F35-LMP1/LMP2-transduced autologous dendritic cells, celecoxib, flow cytometry, immunoenzyme technique, laboratory biomarker analysis | National Cancer Centre, Singapore, Other | 18 Years - N/A | Phase 2 | Interventional | RATIONALE: Vaccines made from a gene-modified virus and a person's dendritic cells may help the body build an effective immune response to kill tumor cells. Celecoxib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving vaccine therapy together with celecoxib may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving vaccine therapy together with celecoxib works in treating patients with metastatic nasopharyngeal cancer. | ||
|
Clinicaltrials.gov | Efficacy and Safety of OncoGel™ Added to Chemotherapy and Radiation Before Surgery in Subjects With Esophageal Cancer | Terminated | Esophageal Cancer, Adenocarcinoma of the Esophagus, Squamous Cell Carcinoma | Drug, Drug, Drug, Radiation, Procedure - OncoGel (Paclitaxel gel), cisplatin, 5-FU, radiation therapy, esophageal resection | BTG International Inc., Other | 18 Years - N/A | Phase 2 | Interventional | OncoGel is a new experimental drug delivery system that allows the slow continuous release of paclitaxel (an approved intravenous anticancer drug), from a gel (ReGel) over a long period of time. The gel will disappear in 4 to 6 weeks as it releases the paclitaxel. The protocol is directed towards evaluating the efficacy and safety of paclitaxel delivered as a local, intralesional treatment when used in combination with chemotherapy (cisplatin and 5-FU) and radiation therapy before surgery. | ||
|
Clinicaltrials.gov | Photodynamic Therapy Using Aminolevulinic Acid in Treating Patients With Oral Leukoplakia | Terminated | Oral Leukoplakia | Drug, Drug, Other - aminolevulinic acid hydrochloride, photodynamic therapy, laboratory biomarker analysis | National Cancer Institute (NCI), NIH | 18 Years - N/A | Phase 1 | Interventional | This phase I trial studies the side effects and best dose of photodynamic therapy using aminolevulinic acid in treating patients with oral leukoplakia. Photodynamic therapy uses a drug, such as aminolevulinic acid, that becomes active when it is exposed to a certain kind of light. When the drug is active, abnormal cells are killed. Photodynamic therapy using aminolevulinic acid may be effective against oral leukoplakia. | ||
|
Clinicaltrials.gov | Phase II Trial for Patients With Loco-Regional Esophageal Carcinoma | Terminated | Loco-regional Esophageal Cancer | Drug, Drug, Drug, Drug, Radiation, Procedure - Bevacizumab, Paclitaxel, Cisplatin, 5-Fluorouracil, Radiation Therapy, Esophagectomy | University of Michigan Rogel Cancer Center, Genentech, Inc., Other, Industry | 18 Years - 75 Years | Phase 2 | Interventional | The purpose of this study is to determine whether bevacizumab can improve the outcome of treatment for patients with esophageal cancer whose disease is confined to the esophagus or the closely surrounding lymph nodes. | ||
|
Clinicaltrials.gov | Radiofrequency Therapy-Induced Endogenous Heat-Shock Proteins With or Without Radiofrequency Ablation or Cryotherapy in Treating Patients With Stage IV Melanoma | Completed | Melanoma (Skin) | Biological, Other, Other, Other, Other, Procedure, Procedure, Procedure - sargramostim, immunoenzyme technique, immunohistochemistry staining method, immunologic technique, laboratory biomarker analysis, biopsy, cryosurgery, radiofrequency ablation | Mayo Clinic, National Cancer Institute (NCI), Other, NIH | 18 Years - 120 Years | Phase 1 | Interventional | RATIONALE: Radiofrequency therapy and radiofrequency ablation use a high-frequency electric current to kill tumor cells. Radiofrequency therapy can also cause the body to produce heat-shock proteins which may help kill more tumor cells. Cryotherapy kills tumor cells by freezing them. It is not yet known whether heat-shock proteins caused by radiofrequency therapy given together with radiofrequency ablation or cryotherapy is more effective in treating stage IV melanoma than radiofrequency therapy-induced heat-shock proteins alone. PURPOSE: This randomized clinical trial is studying the side effects of radiofrequency therapy-induced endogenous heat-shock proteins when given alone or together with radiofrequency ablation or cryotherapy in treating patients with stage IV melanoma. |
Welcome to the RRID Resources search. From here you can search through a compilation of resources used by RRID and see how data is organized within our community.
You are currently on the Community Resources tab looking through categories and sources that RRID has compiled. You can navigate through those categories from here or change to a different tab to execute your search through. Each tab gives a different perspective on data.
If you have an account on RRID then you can log in from here to get additional features in RRID such as Collections, Saved Searches, and managing Resources.
Here is the search term that is being executed, you can type in anything you want to search for. Some tips to help searching:
If you are logged into RRID you can add data records to your collections to create custom spreadsheets across multiple sources of data.
Here are the facets that you can filter the data by.
If you have any further questions please check out our FAQs Page to ask questions and see our tutorials. Click this button to view this tutorial again.
